Synthesis and Evaluation of 2-Amino-4H-Pyran-3-Carbonitrile Derivatives as Antitubercular Agents

Chunxia Chen, Minghui Lu, Zhihui Liu, Junting Wan, Zhengchao Tu, Tianyu Zhang, Ming Yan

Guangzhou Chest Hospital, Guangzhou, China.
Institute of Drug Synthesis and Pharmaceutical Process, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science, Guangzhou, China.

DOI: 10.4236/ojmc.2013.34015                

Abstract

A series of 2-amino-4H-pyran-3-carbonitrile derivatives were designed and synthesized. Their antitubercular activities
were evaluated against autoluminescent M. tuberculosis H37Ra and standard strain M. tuberculosis H37Rv. No obvious
antitubercular activities could be observed (MIC > 10 ug/mL). The results are in sharp contrast with the previously reported
data.

Keywords

2-Amino-4H-Pyran-3-Carbonitrile; Synthesis; Antitubercular Activity

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	World Health Organization, “Global Tuberculosis Control Report 2013,” World Health Organization, Geneva. http://www.who.int/tb/publications/global_report/en/
[2]	L. Christian, G. Philippe, U. Mukund, L. Knut, G. Haileyesus and R. Mario, “Global Tuberculosis Control: Lessons Learnt and Future Prospects,” Nature Reviews Microbiology, Vol. 10, No. 6, 2012, pp. 407-416. http://dx.doi.org/10.1038/nrmicro2797
[3]	World Health Organization, “Multidrug-Resistant Tuberculosis (MDR-TB),” World Health Organization, Geneva. http://www.who.int/tb/challenges/mdr/en/index.html
[4]	M. P. Grobusch, “Drug-Resistant and Extensively Drug-Resistant Tuberculosis in Southern Africa,” Current Opinion in Pulmonary Medicine, Vol. 16, No. 3, 2010, pp. 180-185. http://dx.doi.org/10.1097/MCP.0b013e3283378680
[5]	J. L. Mainardi, J. E. Hugonnet, L. Gutmann and M. Arthur, “Fighting Resistant Tuberculosis with Old Compounds: The Carbapenem Paradigm,” Clinical Microbiology and Infection, Vol. 17, No. 12, 2011, pp. 1755-1756. http://dx.doi.org/10.1111/j.1469-0691.2011.03699.x
[6]	A. G. Nikalje and P. Mudassar, “Multidrug-Resistant Mycobacterium Tuberculosis: A Brief Review,” Asian Journal of Biological Sciences, Vol. 4, No. 2, 2011, pp. 101-115. http://dx.doi.org/10.3923/ajbs.2011.101.115
[7]	R. Shi and I. Sugawara, “Development of New Anti-Tuberculosis Drug Candidates,” Tohoku Journal of Experimental Medicine, Vol. 221, No. 2, 2010, pp. 97-106. http://dx.doi.org/10.1620/tjem.221.97
[8]	S. T. Cole and G. Riccardi, “New Tuberculosis Drugs on the Horizon,” Current Opinion in Microbiology, Vol. 14, No. 5, 2011, pp. 570-576.
[9]	R. R. Kumar, S. Perumal, P. Senthilkumar, P. Yogeeswari and D. Sriram, “An Atomefficient, Solvent-Free, Green Synthesis and Antimycobacterial evaluation of 2-amino-6- Methyl-4-Aryl-8-[(E)-Arylmethylidene]-5,6,7,8-Tetrahy-Dro-4H-Pyrano[3,2-c]Pyridine-3-Carbonitriles,” Bioorganic & Medicinal Chemistry Letters, Vol. 17, No. 23, 2007, pp. 6459-6462. http://dx.doi.org/10.1016/j.bmcl.2007.09.095
[10]	R. R. Kumar, S. Perumal, J. C. Menendez, P. Yogeeswari and D. Sriram, “Antimycobacterial Activity of Novel 1,2,4- Oxadiazole-Pyranopyridine/Chromene Hybrids Generated by Chemoselective 1,3-Dipolar Cycloadditions of Nitrile Oxides,” Bioorganic & Medicinal Chemistry Letters, Vol. 19, No. 11, 2011, pp. 3444-3450. http://dx.doi.org/10.1016/j.bmc.2011.04.033
[11]	Z. P. Hu, C. L. Lou, J. J. Wang, C. X. Chen and M. Yan, “Organocatalytic Conjugate Addition of Malononitrile to Conformationally Restricted Dienones,” The Journal of Organic Chemistry, Vol. 76, No. 10, 2011, pp. 3797- 3804.
[12]	Z. P. Hu, W. J. Wang, X. G. Yin, X. J. Zhang and M. Yan, “Enantioselective Synthesis of 2-Amino-4H-Pyrans via the Organocatalytic Cascade Reaction of Malononitrile and A-Substituted Chalcones,” Tetrahedron: Asymmetry, Vol. 23, No. 22-23, 2012, pp. 461-467.
[13]	H. F. Wang, P. Li, H. F. Cui, X. W. Wang, J. K. Zhang, W. Liu and G. Zhao, “Highly Enantioselective Synthesis of A-Trichloromethyldihydropyrans Catalyzed by Bifunctional Organocatalysts,” Tetrahedron, Vol. 67, No. 10, 2011, pp. 1774-1780. http://dx.doi.org/10.1016/j.tet.2011.01.043
[14]	T. Y. Zhang, S. Y. Li and E. L. Nuermberger, “Autolu-minescent Mycobacterium Tuberculosis for Rapid, Real-Time, Non-Invasive Assessment of Drug and Vaccine Efficacy,” PLoS One, Vol. 7, No. 1, 2012, Article ID: e29774. http://dx.doi.org/10.1371/journal.pone.0029774
[15]	National Committee for Clinical Laboratory Standards, “Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes; Approved Standard,” 2nd Edition, CLSI Document M24-A2, Vol. 31, No. 5, 2011, pp. 3-19.